

SEQUAL TECHNOLOGIES NAMES RANDY STEWARD AS CHIEF OPERATING OFFICER



SeQual Technologies Inc., has announced the appointment of Randy Steward to the position of Chief Operating Officer. Mr. Steward's most recent experience includes working for Spectrum Brands Inc. (Rayovac Corp.) a \$2.5 billion publicly traded global consumer products company with operations in over 100 countries and distribution in more than one million stores. Brand names include: Rayovac, Varta, Remington, Tetra and Cutter. He held the title of Executive Vice President and Chief Financial Officer.

"As corporate operations became more complex due to increased market share with the Eclipse 2 and a more diversified respiratory portfolio, SeQual recognized the value of adding a key executive management position," said Ron Richard, CEO, SeQual Technologies. "We are pleased to have someone of Randy's experience and expertise come aboard."

He is a highly motivated senior executive with extensive operational and financial experience at both private and public companies, including both large mature companies and fast-growth entrepreneurial environments. He is a strategic thinker experienced in setting and achieving aggressive worldwide company objectives. Randy has a proven track record of effectively managing business expansion while instilling financial discipline, streamlining processes and containing costs.

Prior to working with Spectrum Brands he had worked with THER-MOSCAN, INC., San Diego, CA a Division of Braun; a wholly owned subsidiary of The Gillette Company. This was a company who had developed a very successful line of technology applied to human body temperature measurement where he served as President and General Manager. Mr. Steward holds B.B.A., Accounting - Southern Methodist University, Dallas, Texas (1976) CPA and Member of AICPA.

INOVO, INC./CHAD THERAPEUTICS' OXYGEN CONSERVING DEVICES UNAFFECTED BY RECENT ANNOUNCEMENT



Inovo, Inc., based in Naples, Florida, which purchased the oxygen conserving assets and the right to market under the name "CHAD Therapeutics", is issuing a statement to clarify that the company is in no way affiliated with CHAD Therapeutics, Inc., (Chatsworth, CA) which recently announced the suspension of its operations.

Inovo Inc. successfully moved the production of CHAD's oxygen conserving devices to its facility in Naples, Florida in June of this year.

"We continue to emphasize our commitment to both the delivery of high-quality, clinically effective oxygen conservers and the growth of our business for many years to come," states George Harris, CEO of Inovo, Inc.

USING A FAN DURING SLEEP MAY REDUCE INFANTS' SIDS RISK

Infants who slept in a bedroom with a fan ventilating the air had a 72 percent lower risk of Sudden Infant Death Syndrome compared to infants who slept in a bedroom without a fan, according to a new study by the Kaiser Permanente Division of Research. The study appears in the October issue of the Archives of Pediatric & Adolescent Medicine.

This is the first study to examine an association between better air ventilation in infants' bedrooms and reduced SIDS risk.

The finding is consistent with previous research that showed factors influencing a baby's sleep environment may change SIDS risk. Among those factors are sleeping on the stomach and soft bedding, both of which limit air ventilation around an infant's breathing pathway and thus increase the chance of re-breathing exhaled carbon dioxide, said the researchers.

They explained that fan use is no substitute for practices known to reduce the risk for sudden infant death syndrome, which include: always placing infants to sleep on their backs, putting infants to sleep on firm mattresses and avoiding soft bedding materials like comforters and quilts, providing a separate sleep environment, preventing infants from overheating, and not smoking around infants.

VAPOTHERM®'S POISED FOR EXPANSION INTO HOME CARE SEGMENT



Vapotherm, the global leader in High Flow Oxygen Therapy products, has announced that industry veteran Nick Macmillan has joined the company as Manager of its Home Care Segment. Macmillan will be responsible for developing and managing the company's expansion of respiratory therapy products that address chronic and sleep disorders.

Macmillan has been in the health care management and respiratory industry for more than 25 years, having most recently served as National Clinical Director at Rotech Healthcare Inc., one of the top national home care companies in the US, where he was responsible for creating and directing respiratory home care programs. Prior to joining Rotech, Macmillan was the Global Sleep Product Director of Sunrise/DeVilbiss where he oversaw sleep product strategies and successfully executed several product launches.

"Nick's expertise in developing new markets will be invaluable to Vapotherm as we expand our reach into the home care market," said Robert Storey, President & CEO of Vapotherm.

Macmillan is a graduate of Indiana University, Indiana Vocational Technical College and Biosystems Institute. He has held several state and national appointments and elected positions including the President of the Indiana Society for Respiratory Care and Chairperson for the Home Care Section of the American Association for Respiratory Care. In 2003, Nick was inducted as a Fellow of the AARC. He resides in Indianapolis, IN with his wife.

NEW CLINICAL STUDIES SHOW MASIMO TECHNOLOGIES PROVIDE ADVANCED CLINICAL INTELLIGENCE



Masimo, the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low Perfusion pulse oximetry, announced that 13 new independent and objective clinical studies presented at the American Society of Anesthesiology (ASA) Annual Meeting in Orlando, Fla., October 19-21, 2008, found Masimo SET(R) and Masimo Rainbow SET(R) technologies to be crucial in providing clinicians with an early indication of their patients' deteriorating health status in numerous clinical settings, which may allow earlier intervention and prevention of adverse clinical outcomes.

In addition, Masimo's commercial exhibit attracted over 2,500 anesthesiologists from the U.S. and around the world. Anesthesiologists visiting the commercial exhibit marveled at Masimo noninvasive hemoglobin (SpHb(TM)), the first-and-only technology capable of continuously monitoring hemoglobin status. Continuous monitoring of anemic status with Masimo SpHb may allow clinicians to make earlier and better treatment decisions, such as detecting blood loss earlier to initiate more timely transfusions in some patients and avoiding unnecessary blood transfusions in others.

PIVOTAL DATA SHOWED SYMBICORT® IMPROVED LUNG FUNCTION IN ADULTS WITH COPD

Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol significantly improved lung function and was well-tolerated in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) relative to budesonide and formoterol administered alone, and placebo. Both trials showed safety profiles consistent with the established profiles in asthma for each product. In addition, an analysis of these trials showed that patients receiving SYMBICORT achieved a bronchodilatory effect, or opening of the airways, similar to formoterol DPI, and a more rapid effect than that achieved by either budesonide pMDI or placebo. Results were presented at CHEST 2008, the 74th annual international scientific assembly of the American College of Chest Physicians, held in Philadelphia, October 25-30, 2008.

In April 2008, AstraZeneca submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SYMBICORT for the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. SYMBICORT is a combination therapy currently indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older. SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.